Get access

Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys

Authors

  • Pershia Samadi PhD,

    1. Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada
    2. Département de Médecine, Faculté de Médecine, Université Laval, Quebec City, QC, Canada
    Search for more papers by this author
  • Laurent Grégoire BSc,

    1. Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada
    2. Département de Médecine, Faculté de Médecine, Université Laval, Quebec City, QC, Canada
    Search for more papers by this author
  • Claude Rouillard PhD,

    1. Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada
    2. Département de Médecine, Faculté de Médecine, Université Laval, Quebec City, QC, Canada
    Search for more papers by this author
  • Paul J. Bédard MD, PhD,

    1. Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada
    2. Département de Médecine, Faculté de Médecine, Université Laval, Quebec City, QC, Canada
    Search for more papers by this author
  • Thérèse Di Paolo PhD,

    1. Laboratoire d'Endocrinologie Moléculaire et Oncologie, CHUQ, Faculté de Pharmacie, Université Laval, Quebec City, QC, Canada
    Search for more papers by this author
  • Daniel Lévesque PhD

    Corresponding author
    1. Centre de recherche en Neurosciences, Centre Hospitalier Universitaire de Québec (CHUQ), Ste-Foy, Quebec, Canada
    2. Département de Médecine, Faculté de Médecine, Université Laval, Quebec City, QC, Canada
    • Neuroscience Unit, RC-9800, CHUL Research Center (CHUQ), 2705, Boulevard Laurier, Ste-Foy, Quebec, Canada G1V 4G2
    Search for more papers by this author

Abstract

Objective

The objective of the present study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–treated monkeys.

Methods

We explored the effect of DHA in two paradigms. First, a group of MPTP monkeys was primed with levodopa for several months before introducing DHA. A second group of MPTP monkeys (de novo) was exposed to DHA before levodopa therapy.

Results

DHA administration reduced LIDs in both paradigms without alteration of the anti-parkinsonian effect of levodopa indicating that DHA can reduce the severity or delay the development of LIDs in a nonhuman primate model of Parkinson's disease.

Interpretation

These results suggest that DHA can reduce the severity or delay the develoment of LIDs in a nonhuman primate model of Parkinson's disease. DHA may represent a new approach to improve the quality of life of Parkinson's disease patients. Ann Neurol 2006;59:282–288

Get access to the full text of this article

Ancillary